Migra-Therapeutics, LLC
Atlanta, GA Biopharmaceutical
- UEI
- NCN6HK3N2SG3
- CAGE
- 88L90
- Primary NAICS
- 621511 Medical Laboratories
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Partnership or Limited Liability Partnership
- SAM.gov registration date
- Physical address
- 1750 Haygood Dr NE, Atlanta, GA 30307, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Theranostec Inc. | Carmichael, CA | 541713 Research and Development in Nanotechnology |
| PDX Pharmaceuticals Inc. | Portland, OR | 541713 Research and Development in Nanotechnology |
| Senex Biotechnology Inc. | Maynard, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Ocean Nano TECH LLC | San Diego, CA | 541713 Research and Development in Nanotechnology |
| Leukogene Therapeutics Inc. | Mount Pleasant, SC | — |
About the company
Migra-Therapeutics, LLC Biopharmaceutical Division, doing business as Migra-Therapeutics LLC, is a woman-owned small business registered to receive federal contracts and grants. It is structured as a partnership or limited liability partnership and specializes in the development of targeted nanoparticle drug delivery systems for cancer therapy.
Migra-Therapeutics LLC has received several multi-year federal grant awards from the National Cancer Institute (NCI) within the National Institutes of Health (NIH) for the development of a targeted and stroma-penetrating nanoparticle drug delivery system for pancreatic cancer therapy. These projects aim to overcome the challenges of drug resistance and inefficient delivery in pancreatic cancer by developing a hyaluronic acid nanoparticle carrying SN38, an active metabolite of the chemotherapy drug irinotecan. The nanoparticles are designed to target and penetrate the dense fibrous tumor stroma, allowing for more effective drug delivery to pancreatic cancer cells. The grant awards have supported preclinical studies, optimization of nanoformulations, GLP/GMP production, toxicity and pharmacokinetic studies, and evaluation in patient-derived xenograft models. The ultimate goal is to obtain FDA approval for a Phase 1 clinical trial of this novel nanodrug in advanced pancreatic cancer patients.
Quick answers
Is Migra-Therapeutics, LLC registered in SAM.gov?
Yes. Migra-Therapeutics, LLC's SAM.gov registration is active through April 28, 2027.
What is Migra-Therapeutics, LLC's most recent federal award?
Migra-Therapeutics, LLC's most recent federal grant award is Tumor stroma breaking system for efficient delivery of therapeutic agents (R41CA247165), from National Cancer Institute (NIH), on June 23, 2020.
On GovTribe
See Migra-Therapeutics, LLC's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors